Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

AnHeart’s investigational medicine taletrectinib shrank tumors in more than 90% of people with ROS1+ NSCLC who were ROS1 TKI naïve in TRUST-II trial ...

ROS1 is a gene which can join (or fuse) with part of another gene. The fusion activates the ROS1 gene in a way that causes uncontrolled cancer cell growth. The gene change is called ROS1 fusion.

Crizotinib treatment effective against ROS1-positive lung cancer, study suggests Date: September 27, 2014 Source: Massachusetts General Hospital Summary: ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities analyst Silvan Tuerkcan maintained a “Market Outperform” rating on Nuvation’s ...

“ROS1 fusions occur in approximately two percent of all cases of NSCLC and, given the propensity for these tumors to metastasize to the brain, the CNS ...

Title: Crystal structure of drug-resistant ROS1 G2032R in complex with zidesamtinib, a clinical-stage ROS1 inhibitor with best-in-class potential Authors: Joseph M. Magrino * 1, Anupong ...

Brain metastases were found to be fairly common in stage IV ROS1-positive cancers and in 47 percent of ROS1 patients, the brain was the first and only site of progression.

ROS1 rearranged or ROS1-positive non-small cell lung cancer is a subtype of lung cancer that is — makes up about 1 to 2% of non-small cell lung cancer. And it's a … really interesting subtype, because ...

The Food and Drug Administration (FDA) has granted a breakthrough therapy designation to Xalkori (crizotinib) as a potential treatment for patients with ROS1-positive non—small cell lung cancer (NSCLC ...